EGFR and adenocarcinoma: A retrospective study suggested that among 6698 patients with adenocarcinoma, 35 patients had s768i mutations and 22 had combined sensitive mutations; the objective response rate (ORR) of lung cancer patients with p.s768i + p.l858r after EGFR‐TKI treatment was 60%.16